Albert David Ltd

₹ 708 -1.17%

20 May 10:38 a.m.

albertdavidindia.com BSE: 524075 NSE: ALBERTDAVD

About

Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products^[1]

Key Points

Business Overview:^[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.

Website BSE NSE

Market Cap ₹ 404 Cr.
Current Price ₹ 708
High / Low ₹ 959 / 580
Stock P/E
Book Value ₹ 686
Dividend Yield 0.71 %
ROCE 0.77 %
ROE -0.38 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Stock is trading at 1.04 times its book value

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 6.25% over past five years.
Company has a low return on equity of 8.07% over last 3 years.
Earnings include an other income of Rs.7.45 Cr.
Working capital days have increased from 80.3 days to 247 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	81	92	93	88	89	89	98	83	75	71	87	90	86
	72	79	77	80	79	88	92	82	80	81	85	79	83
Operating Profit	10	13	16	8	10	1	6	1	-5	-11	3	11	3
OPM %	12%	14%	17%	9%	11%	1%	6%	1%	-6%	-15%	3%	12%	3%
	0	18	12	17	10	23	21	-9	-5	22	-2	12	-25
Interest	0	0	0	0	0	0	0	0	0	1	1	1	0
Depreciation	2	2	1	2	2	2	2	2	2	2	2	2	3
Profit before tax	7	29	27	23	18	22	25	-10	-12	8	-3	20	-25
Tax %	48%	20%	24%	20%	29%	15%	28%	-8%	-13%	6%	28%	23%	-15%
	4	23	20	19	13	19	18	-9	-10	8	-3	15	-21
EPS in Rs	6.54	41.16	35.57	32.80	22.62	33.01	31.66	-16.45	-18.10	13.91	-5.78	26.81	-37.55
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	317	318	293	285	316	320	246	313	341	362	345	334
	281	286	266	267	286	289	227	272	297	315	342	328
Operating Profit	37	31	27	18	30	30	19	41	44	47	3	5
OPM %	12%	10%	9%	6%	10%	10%	8%	13%	13%	13%	1%	2%
	2	43	8	9	15	7	17	16	15	58	30	7
Interest	3	2	1	1	1	1	1	1	1	0	1	3
Depreciation	15	9	8	8	7	8	8	9	9	7	7	10
Profit before tax	20	63	26	18	38	29	27	47	51	97	25	1
Tax %	32%	24%	39%	45%	29%	34%	19%	25%	29%	22%	32%	379%
	14	48	16	10	27	19	22	35	36	75	17	-1
EPS in Rs	24.00	84.10	27.96	17.24	46.68	33.59	38.79	61.78	63.38	132.15	30.14	-2.61
Dividend Payout %	23%	7%	20%	32%	13%	21%	15%	15%	14%	9%	17%	-192%

Compounded Sales Growth
10 Years:	0%
5 Years:	6%
3 Years:	-1%
TTM:	-3%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-109%

Stock Price CAGR
10 Years:	9%
5 Years:	10%
3 Years:	6%
1 Year:	-12%

Return on Equity
10 Years:	9%
5 Years:	10%
3 Years:	8%
Last Year:	0%

Balance Sheet

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6	6	6	6	6	6	6	6	6	6	6	6
Reserves	87	131	177	180	205	217	239	274	306	377	387	386
	30	20	30	28	0	2	2	6	5	3	12	30
	71	67	71	76	84	95	95	116	106	112	107	98
Total Liabilities	193	224	285	290	295	320	341	401	423	498	511	519
	49	44	87	83	77	91	84	88	80	83	99	100
CWIP	5	5	9	5	5	2	1	1	3	7	2	21
Investments	16	48	59	68	113	122	138	183	193	273	260	243
	122	127	130	134	99	106	119	130	148	135	151	155
Total Assets	193	224	285	290	295	320	341	401	423	498	511	519

Cash Flows

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	28	68	20	30	32	30	37	40	11	46	-28	-8
	-9	-38	-36	-11	-19	-20	-37	-40	-5	-33	23	-4
	-18	-18	7	-5	-17	-10	-2	-2	-6	-8	0	12
Net Cash Flow	1	12	-10	15	-4	0	-2	-1	-1	4	-5	-0
Free Cash Flow	18	62	-0	31	45	15	35	32	6	35	-43	-36
CFO/OP	95%	303%	115%	204%	126%	149%	202%	129%	59%	131%	-629%	-49%

Ratios

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	47	41	41	35	25	34	29	29	32	30	29	37
Inventory Days	176	187	217	173	151	148	151	124	149	126	201	187
Days Payable	103	102	117	127	102	132	104	96	95	98	118	104
Cash Conversion Cycle	120	126	141	81	74	50	76	57	87	58	112	120
Working Capital Days	27	25	24	10	21	18	-10	-34	14	-13	6	247
ROCE %	18%	17%	15%	7%	18%	14%	12%	17%	17%	28%	6%	1%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Revenue from Large Volume Parenterals
₹ Lakhs

x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	xx,xxx.xx	x,xxx.xx
x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx
							x,xxx	x,xxx	x,xxx	x,xxx
								xx	xx	xx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Revenue from Syrups/Liquids
₹ Lakhs

Total Number of Permanent Employees
Number

Number of Stockists
Number

Contribution of Top Product (Placentrex)
%

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	62.04%	62.04%	62.04%	62.13%	62.13%	62.13%	62.13%	62.23%	62.23%	62.23%	62.23%	62.23%
	0.65%	0.57%	0.70%	0.98%	0.80%	0.88%	0.86%	1.00%	0.84%	0.60%	0.60%	0.58%
	2.30%	1.90%	1.67%	1.67%	1.67%	1.63%	1.63%	1.64%	1.65%	1.65%	1.65%	1.65%
	35.01%	35.49%	35.60%	35.23%	35.41%	35.36%	35.39%	35.12%	35.27%	35.50%	35.51%	35.52%
No. of Shareholders	9,828	9,907	10,041	11,266	12,349	13,590	14,830	15,304	15,070	14,666	13,967	13,555

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	60.90%	60.90%	60.90%	61.15%	61.25%	61.96%	62.04%	62.13%	62.23%	62.23%
	0.00%	0.00%	0.12%	0.00%	0.00%	0.75%	0.57%	0.98%	1.00%	0.58%
	4.56%	4.61%	4.47%	3.91%	3.81%	3.18%	2.80%	1.67%	1.64%	1.65%
	34.54%	34.49%	34.51%	34.94%	34.94%	34.11%	34.59%	35.23%	35.12%	35.52%
No. of Shareholders	8,969	7,815	8,906	8,595	12,011	10,645	9,786	11,266	15,304	13,555

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Albert David Ltd

Albert David Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings